BioSante Pharmaceuticals, Inc. engages in the licensing and development of hormone therapy products to treat men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. The company's lead products include Elestrin, a transdermal bioidentical estrogen gel for the treatment of menopausal symptoms in women; and LibiGel, a transdermal bioidentical testosterone gel, which is in Phase III development for the treatment of female sexual dysfunction. Its other products include Bio-E/P-Gel, a transdermal combination gel of bioidentical estrogen and a progestogen for treatment of menopausal symptoms in women; LibiGel-E/T, a transdermal combination gel of bioidentical estrogen and bioidentical testosterone for treatment of female sexual dysfunction in menopausal women; Bio-T-Gel, a transdermal bioidentical testosterone gel for treatment of hypogonadism, or testosterone deficiency in men; and triple hormone contraceptives. BioSante is also developing its calcium phosphate nanotechnology (CaP) for vaccines, including hepatitis B, avian flu, and biodefense vaccines for toxins, such as anthrax, as well as a system for delivering drugs through alternative routes of administration. Its CaP products under development comprise BioVant, a proprietary CaP adjuvant and delivery technology for vaccines against cancer, viral and bacterial infections, and autoimmune diseases; BioOral, a delivery system for oral/buccal/intranasal administration of proteins and other therapies; BioAir, a delivery system for inhalable versions of proteins and other therapies; and BioCap, which is used in the field of aesthetic medicine. The company was founded in 1996 and is headquartered in Lincolnshire, Illinois.